|Bid||1.6800 x 4000|
|Ask||1.9400 x 2900|
|Day's Range||1.8000 - 2.0500|
|52 Week Range||1.6600 - 9.2000|
|Beta (5Y Monthly)||2.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today financial results for the first quarter ended March 31, 2022 and provided a corporate update on key events since the start of 2022.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Mr. Ari Krashin, Chief Financial Officer and Chief Operating Officer of Compugen Ltd. (the "Company"), notified the Company of his wish to depart from his position at the Company to pursue other interests. Mr. Krashin will leave in August 2022 and, until his departure, he will continue to support the Company in his current roles. The departure is not r